MESO vs STOK: fair value comparison
Mesoblast Limited and Stoke Therapeutics, Inc. · Updated 2026-10-19
MESO's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. STOK has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, MESO currently ranks higher by quality score.
| MESO | STOK | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $13.28 | $24.17 |
| 12-month range | $13.19–$20.96 | $22.37–$38.35 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #105 of 301 Healthcare | #107 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | — | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Downtrend |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: MESO fair value analysis · STOK fair value analysis